or 2-amino-3-hydroxypyridine. A similar approach, how-
ever, is not directly applicable to the pyrido[2,3-b][1,4]-
oxazine ring system. On the other hand, it was felt that
the Smiles rearrangement could be exploited to circum-
vent this limitation. Since the Smiles rearrangement
necessitates an electron-deficient center to proceed at a
reasonable rate, we selected 2-haloacetamide and 2-halo-
3-hydroxypyridine as the reaction partners.
In exploratory experiments, reaction of 2-bromo-3-
hydroxypyridine (2a ) with N-benzyl-2-chloroacetamide
(1a ) in the presence of potassium carbonate furnished
N-benzyl-2-(2-bromopyridin-3-yloxy)acetamide (3a ) as the
major product and bicyclic adduct 4a as only a minor
product (Scheme 1). Subsequent exposure of 3a to cesium
carbonate induced cyclization and gave 4a quantitatively.
Spectral and physical comparisons (IR, 1D/2D-NMR,
NOE, mp) of 4a cogently demonstrated it was different
from 4-benzyl-4H-pyrido[3,2-b][1,4]oxazin-3-one (5), pre-
pared from commercial 2H-pyrido[3,2-b][1.4]oxazin-3-one
and benzyl chloride with potassium carbonate. X-ray
analysis unambiguously confirmed the structure of 4a
as 1-benzyl-1H-pyrido[2,3-b][1,4]oxazin-2-one.
A On e-P ot Syn th esis of
P yr id o[2,3-b][1,4]oxa zin -2-on es
Su-Dong Cho,† Yong-Dae Park,‡ J eum-J ong Kim,‡
Sang-Gyeong Lee,‡ Chen Ma,† Sang-Yong Song,†
Woo-Hong J oo,† J . R. Falck,§ Motoo Shiro,
Dong-Soo Shin,*,† and Yong-J in Yoon*,‡
Department of Chemistry and Research Institute of
Natural Sciences, Changwon National University,
Changwon 641-773, Korea, Department of Chemistry and
Research Institute of Natural Science, Gyeongsang National
University, Chinju 660-701, Korea, Department of
Biochemistry, University of Texas Southwestern Medical
Center, Dallas, Texas 75390, and Rigaku Corporation,
3-9-12 Matsubara-cho, Akishima-shi,
Tokyo 196-8666, J apan
yjyoon@nongae.gsnu.ac.kr
Received May 7, 2003
Abstr a ct: Pyrido[2,3-b][1,4]oxazin-2-ones are conveniently
prepared in excellent yields by a one-pot annulation of
N-substituted-2-chloroacetamides with 2-halo-3-hydroxypyr-
idines with use of cesium carbonate in refluxing acetonitrile.
The key transformation features a Smiles rearrangement
of the initial O-alkylation product and subsequent cycliza-
tion.
The overall annulation is best explained by a three-
step process (Scheme 2). Alkylation of 1 by 2 generates
adduct 3, which can be observed by TLC monitoring. Rate
(2) (a) Kuroita, T.; Marubayashi, N.; Sano, M.; Kanzaki, K.; Inaba,
K.; Kawakita, T. Chem. Pharm. Bull. 1996, 44, 2051. (b) Kawakita,
T.; Kawakita, T.; Kuroita, T.; Yasumoto, M.; Sano, M.; Inaba, K.;
Fukuda, T.; Tahara, T. Chem. Pharm. Bull. 1992, 40, 624. (c) Kuroita,
T.; Sakamori, M.; Kawakita, T. Chem. Pharm. Bull. 1996, 44, 756. (d)
Hasegawa, K.; Ito, S.; Inoue, S.; Wakamatsu, K.; Ozeki, H.; Ishiguro,
I. Biochem. Pharm. 1997, 53, 1435. (e) Taverne, T.; Diouf, O.; Depreux,
P.; Poupaet, J . H.; Lesieur, D.; Guardiola-Lemaitre, B.; Renard, P.;
Rettori, M. C.; Caignard, D. H.; Pfeiffer, B. J . Med. Chem. 1998, 41,
2010. (f) Belliotti, T. R.; Wustrow, D. J .; Brink, W. A.; Zoski, K. T.;
Shih, Y.-H.; Whetzel, S. Z.; Georgic, L. M.; Corbin, A. E.; Akunne, H.
C.; Heffner, T. G.; Pugsley, T. A.; Wise, L. D. J . Med. Chem. 1999, 42,
5181. (g) Caliendo, G.; Perissutti, E.; Santagada, V.; Fiorino, F.;
Severino, B.; Bianca, R.; d’Emmanuele di V.; Lippolis, L.; Pinto, A.;
Sorrentino, R. Bioorg. Med. Chem. 2002, 10, 2663. (h) Macchiarulo,
A.; Costantino, G.; Fringuelli, D.; Vecchiarelli, A.; Schiaffella, F.;
Fringuelli, R. Bioorg. Med. Chem. 2002, 10, 3415. (i) Matsumoto, Y.;
Tsuzuki, R.; Matsuhisa, A.; Yoden, T.; Yamagiwa, Y.; Yanagisawa, I.;
Shibanuma, T.; Nohira, H. Bioorg. Med. Chem. 2000, 8, 393. (j)
Caliendo, G.; Grieco, P.; Perissutti, E.; Santagada, V.; Santini, A.;
Albrizio, S.; Fattorusso, C.; Pinto, A.; Sorrentino, R. Eur. J . Med. Chem.
1998, 33, 957. (k) Mitscher, L. A.; Sharma, P. N.; Chu, D. T. W.; Shen,
L. L.; Pernet, A. G. J . Med. Chem. 1987, 30, 2283.
(3) (a) Savelon, L.; Bizot-Espiard, J . G.; Caignard, D. H.; Pfeiffer,
B.; Renard, P.; Viaud, M. C.; Guillaumet, G. Bioorg. Med. Chem. 1998,
6, 133. (b) Matsumoto, Y.; Tsuzuki, R.; Matsuhisa, A.; Masuda, N.;
Yamagiwa, Y.; Yanagisawa, I.; Shibanuma, T.; Nohira, H. Chem.
Pharm. Bull. 1999, 47, 971. (c) Spada, A. P.; Studt, W. L.; Campbell,
H. F.; Kuhla, D. E. U.S. Patent 4,822,794, 1989. (d) Krapcho, J . U.S.
Patent 3,984,405, 1976.
(4) Buckman, B.; Mohan, R.; Koovakkat, S.; Liang, A.; Trinh, L.;
Morrissey, M. M. Bioorg. Med. Chem. Lett. 1998, 8, 2235.
(5) (a) Breznik, M.; Hrast, V.; Mrcina, A.; Kikelj, D. Tetrahedron:
Asymmetry 1999, 10, 153. (b) Rutar, A.; Kikelj, D. Synth. Commun.
1998, 28, 2737. (c) Kudo, N.; Furuta, S.; Sato, K. Chem. Pharm. Bull.
1996, 44, 1663. (d) Yamazaki, A.; Achiwa, I.; Achiwa, K. Tetrahedron:
Asymmetry 1996, 7, 403.
The wide occurrence of benzo-fused and heterocycle-
fused [1,4]oxazines in bioactive natural products and
pharmaceuticals has made them important synthetic
targets.1 For the most part, synthetic routes to benzo-
[1,4]oxazines,2 pyrido[3,2-b][1,4]oxazines,3 and pyrimido-
[5,4-b][1,4]oxazines4 are well established.5,6 In contrast,
pyrido[2,3-b][1,4]oxazines have received scant attention.7
As part of our continuing interest in the development of
economic syntheses of heterocyclic systems, we investi-
gated the utility of the Smiles rearrangement8 and report
herein its application to the synthesis of pyrido[2,3-b]-
[1,4]oxazin-2-ones using readily available, stable precur-
sors.
Typically, benzo[1,4]oxazines and pyrido[3,2-b][1,4]-
oxazines are made by the direct cyclization of 2-haloacetyl
halides or alkyl 2-halopropionates with 2-aminophenol
* Address correspondence to Yong-J in Yoon: Gyeongsang National
University. Phone: 082-055-751-6019. Fax: 082-055-761-0244.
† Department of Chemistry, Research Institute of Natural Sciences,
and Changwon National University.
‡ Gyeongsang National University.
§ University of Texas Southwestern Medical Center.
Rigaku Corporation.
(1) (a) Bourlot, A.-S.; Sanchez, I.; Dureng, G.; Guillaumet, G.;
Massingham, R.; Monteil, A.; Winslow, E.; Pujol, M. D.; Me´rour, J .-Y.
J . Med. Chem. 1998, 41, 3142. (b) Combs, D. W.; Rampulla, S. C.; Bell,
S. C.; Klaubert, D. H.; Tobia, A. J .; Falotico, R.; Haertlein, B.; Lakas-
Weiss, C.; Moor, J . B. J . Med. Chem. 1990, 33, 380. (c) Baxter, E. W.;
Reitz, A. B. Bioorg. Med. Chem. Lett. 1997, 7, 763. (d) Matsuoka, H.;
Ohi, N.; Mihara, M.; Suzuki, H.; Miyamoto, K.; Muruyama, N.; Tsuji,
K.; Kato, N.; Akimoto, T.; Takeda, Y.; Yano, K.; Kuroki, T. J . Med.
Chem. 1997, 40, 105. (e) Largeron, M.; Lockart, B.; Pfeiffer, B.; Fleury,
M. B. J . Med. Chem. 1999, 42, 5043. (f) Hofmann, A.; Sicker, D. J .
Nat. Prod. 1999, 62, 1151. (g) Otsuka, H.; Hirai, Y.; Nagao, T.;
Yamasaki, K. J . Nat. Prod. 1988, 51, 74. (h) Tomigahara, Y.; Onogi,
M.; Kaneko, H.; Nakatsuka, I.; Yamane, S. J . Agric. Food Chem. 1999,
47, 2429. (i) Lyans, P. C.; Hipskind, H. D.; Wood, K. V.; Nicholson, R.
L. J . Agric. Food Chem. 1988, 36, 57.
(6) (a) Arrault, A.; Touzeau, F.; Guillaumet, G.; Le´ger, J .-M.; J arry,
C.; Me´rour, J .-Y. Tetrahedron 2002, 58, 8145. (b) Kikelj, D.; Suhadolc,
E.; Urleb, U.; Zbontar, U. J . Heterocycl. Chem. 1993, 30, 597. (c)
Clauson-Kaas, N.; Heide, H.; Olsen, G. Acta Chem. Scand. 1969, 23,
2322.
(7) (a) Heilmann, D.; Sicker, D. J . Prakt. Chem. 1990, 332, 265. (b)
Heilmann, D.; Siehr, I.; Beerbalk, H.-D.; Kempter, G.; Koeppel, H. Z.
Chem. 1986, 26, 99. (c) Balko, T. W.; Brinkmeyer, R. S. J . Heterocycl.
Chem. 1987, 24, 901.
(8) Bunnett, J . F.; Zahler, R. E. Chem. Rev. 1951, 49, 362.
10.1021/jo034593i CCC: $25.00 © 2003 American Chemical Society
Published on Web 09/06/2003
7918
J . Org. Chem. 2003, 68, 7918-7920